Abstract
Patients with insulin-secreting islet cell tumors are at risk for severe, protracted hypoglycemia. Surgical removal of the tumor is the treatment of choice. During the diagnostic work up, medical treatment for hypoglycemia is often mandatory, while adequate protection against hypoglycemia during operation is sometimes difficult to achieve. In cases of malignant (metastatic) insulinomas, curative surgery is, in most instances, not possible, necessitating additional (medical) therapy to protect these patients from damage caused by hypoglycemic attacks.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Alberti K. G. M. M., Christensen N. J., Christensen S. E., Prange-Hanse J., Iversen J., Lundbaek K., Syer-Hansen K., Ørskov H.: Inhibition of insulin secretion by somatostatin. Lancet 1973; ii:1299–1301
Bruining G. J., Bosschaart A. N., Aarsen R. S. R., Lamberts S. W. J., Sauer P. J. J., del Pozo E.: Normalization of glucose homeostasis by a long-acting somatostatin analogue SMS 201–995 in a newborn with nesidioblastosis. Acta Endocrinol 1986; 113:334–340
Christensen S. E., Hansen A. P., Lundbaek K., Ørskov H., Syer-Hansen K.: Somatostatin and insulinomas. Lancet 1975; i:1426
Lamberts S. W. J., Reubi J. C., Uitterlinden P., Zuiderwijk J., van den Werff P., van Hal P.: Studies on the mechanism of action of the inhibitory effect of the somatostatin analogue SMS 201–995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315 a. Endocrinology 1986; 118:2188–2194
Lamberts S. W. J., Uitterlinden P., Verschoor L., van Dongen K. J., del Pozo E.: Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 1986; 313:1576–1580
Lamberts S. W. J., Pieters G. F. F. M., Metselaar H. X, Ong G. L., Tan H. S., Reubi J. C.: Patients with metastatic endocrine pancreatic tumors seldom escape from therapy with a long-acting somatostatin analogue. Acta Endocrinol (Copenh) 1988; in press
Lorenzi M., Gerich J. E., Karam J. H., Forsham P. H.: Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool. J Clin Endocrinol Metab 1975; 40:1121–1124
Reubi J. C.: A somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth. Acta Endocrinol 1985; 109:108–114
Reubi J. C., Rivier J., Perrin M., Brown M., Vale W.: Specific high affinity binding sites for somatostatin-28 on pancreatic β-cells: Differences with brain somatostatin receptors. Endocrinology 1982; 110:1049–1051
Reubi J. C., Häcki W., Lamberts S. W. J.: Hormone-producing gastrointestinal tumors contain high density of somatostatin receptors: diagnosticai and therapeutic implications. J Clin Endocrinol Metab 1987; 65:1127–1135
Verschoor L., Uitterlinden P., Lamberts S. W. J., del Pozo E.: On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clin Endocrinol 1986; 25:555–560
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer Verlag, Berlin Heidelberg
About this paper
Cite this paper
Lamberts, S.W.J., Reubi, JC. (1989). The Use of Sandostatin® in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis. In: O’Dorisio, T.M. (eds) Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61328-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-61328-9_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64794-9
Online ISBN: 978-3-642-61328-9
eBook Packages: Springer Book Archive